Abstract: The Gynecologic Cancer InterGroup (GCIG) has developed from a small net work of ovarian cancer researchers to a large international forum addressing multiple issues related to research in gynecologic cancers. Member groups of the GCIG have collaboratively conducted pivotal clinical trials in cancers of the ovary, endometrium, and cervix. The par ticipation of operational and statistical personnel from the GCIG member groups has facili tated a collegial approach to international differences and restrictions. One of the powerful initiatives of the GCIG is the facilitation of the Ovarian Cancer Consensus Conference every few years. The 4th Ovarian Cancer Consensus Conference was held in Vancouver, Canada, in June 2010, and the resulting publications (herein) provide an invaluable resource to researchers in the field of gynecologic oncology.
history of the GCIG, methods of the conference consensus process, and outstanding issues to be considered in ovarian cancer were all published the following year. 6Y8 Building on this momentum, the GCIG has grown considerably, from 13 international gynecologic cancer research groups to 23 full member groups and now includes an additional number of interested/observer organizations (Table 1) . Full member groups must have a published record of independently con ducting meaningful phase 3 randomized trials in populations of women affected by gynecologic cancer.
In June 2010, the fourth OCCC was held in Vancouver, Canada. The resulting series of articles published in this journal reflect not only the degree to which consensus was reached but also the enormous commitment to global col laboration among the current members of the GCIG.
BACKGROUND OF THE GCIG
After the successful international collaboration be tween European and Canadian investigators in 2 ovarian can cer clinical trials, 9, 10 it was determined by the leaders of the EORTC Gynecological Cancer Group, the NCI Canada Clinical Trials Group (CTG), the Nordic Society of Gyne cologic Oncology (NSGO), the Scottish Gynecological Cancer Trials Group (SGCTG), the Southwestern Oncology Group (SWOG), and the Arbeitsgemeinschaft Gynaekologische On kologie studiengruppe (AGO) that further cooperation in a sentative from each member group. National groups with a research track record, who agree to pay dues and comply with the statutes, can be selected. Less experienced groups can be accepted with observer status and then potentially with provi sional member status.
The GCIG is a cooperative of national gynecologic cancer clinical trials groups, each of which is allowed 6 representatives; typically 3 or 4 clinical investigators, a stat istician, and a trials manager. The GCIG Membership Com mittee is formed from the 3 most recent past-chairs and follows strict criteria in review of applications and recom mendations to the Executive Board. Member groups are reviewed every 2 years concerning participation in GCIG Copyright © 2011 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited.
studies, representation at GCIG meetings, compliance with good clinical practice, and payment of dues.
UPDATE OF THE GCIG (2010)
Member groups of GCIG have collaboratively con ducted a number of pivotal phase 3 clinical trials that have ultimately defined the standard of care for women with gy necologic cancers. In addition to the fore-mentioned trials, 9, 10 others include the evaluation of intraperitoneal chemother apy in primary treatment of ovarian cancer, 11 paclitaxel, 12 and liposomal doxorubicin 13 in the treatment of recurrent disease, the addition of anthracycline (epirubicin) to standard ther apy in ovarian cancer, 14, 15 platinum-based chemoradiation for cancer of the cervix, 16 and systemic chemotherapy for endo metrial cancer. 17 Data from clinical trials conducted by GCIG groups have been used to support licensing applications for paclitaxel, 9 gemcitabine, 18 and topotecan 19 in the treatment of ovarian cancer.
Ovarian cancer chemotherapy trials have dominated GCIG activity, but during recent years, the GCIG has been working to develop trials in cervical and endometrial cancer. In 2006, a GCIG workshop was convened to review the research areas of need for endometrial cancer to follow the ASTEC/EN5 and PORTEC 1 and 2 trials, and as a result, collaborative GCIG trials addressing systemic therapy are now underway, for example, PORTEC 3. In 2009, a similar platform dedicated to cervical cancer was conducted by the GCIG. Because there was particular emphasis on achieving greater involvement by groups from developing countries, a ''cervix cancer research network'' is currently being estab lished under the GCIG umbrella. A number of trials are un der development, led by GCIG groups with participation from the cervix cancer research network. These trials include induction chemotherapy and consolidation chemotherapy be fore and after chemoradiation for advanced disease and radi cal versus less radical surgery for early cervical cancer. As one of the GCIG aims is to maintain a portfolio of surgical trials, currently these too are under development, including trials in surgery for recurrent ovarian cancer and lymphadenectomy for endometrial and ovarian cancer.
Each disease site (ovary, endometrial [including gesta tional trophoblastic disease] and cervix [including vagina and vulva]) has a standing committee where investigators discuss and develop collaborative trial concepts and protocols. The Harmonization standing committee has proven to be an in valuable resource in facilitating international collaboration, tackling the challenges of conducting trials through the efforts of the operational and statistician representatives. The Trans lational Research standing committee has likewise proved in valuable, addressing the challenges of tissue collection provided by clinical trial participants, which becomes increasingly im portant in an era of personalized medicine where biomarker led trials will become the criterion standard for targeted therapy.
Working groups in the GCIG are formed as deemed necessary by the Executive Board; some with defined projects such as the Screening/Prevention, Classifications, Federation Internationale Gynecologie et Obstetrique (FIGO) review, Response and Progression, and Education working groups; whereas others involve long-term initiatives, such as the Rare Tumors and Symptom Benefit working groups.
The GCIG has evolved as a forum for communication and exchange of ideas and provides the means by which international intergroup collaborations and consensus can be fostered. GCIG criteria have become the standard for evalu ating treatment response 20, 21 and, as of the fourth OCCC, end points have been agreed on for incorporation into GCIG clinical trials.
The GCIG meets face to face twice a year, spring in North America and autumn in Europe, generally in conjunc tion with other major (gynecologic) cancer conferences. The Executive Board and subgroups convene by teleconference throughout the year as needed, ensuring business is conducted year-round.
With a clear mission statement to promote and conduct high-quality clinical trials to improve outcomes for women with gynecologic cancers, the GCIG has become a highly suc cessful and respected organization. This is achieved through international collaboration, a strong sense of common purpose, shared expertise, and mutual respect among members.
Through an enormous volunteer commitment by many experts in the field who recognize the need for collaborative international work and the increasing interdependence of research groups, the foci of the GCIG are to:
1. promote international cooperation, 2. promote clinical research, 3. perform studies in rare tumors, 4. stimulate evidence based medicine, and 5. support educational activities.
Currently, the GCIG Web site (www.gcig.igcs.org) is the major source for resources and up-to-date information.
